Osteoporosis Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies – Haoma Medica, Jiangsu HengRui Medicine

January 19 21:29 2023
Osteoporosis Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies - Haoma Medica, Jiangsu HengRui Medicine
The Osteoporosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteoporosis pipeline products will significantly revolutionize the Osteoporosis market dynamics.

DelveInsight’s “Osteoporosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Osteoporosis, historical and forecasted epidemiology as well as the Osteoporosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Osteoporosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Osteoporosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Osteoporosis Market Insights

 

Osteoporosis Overview

Osteoporosis is defined as a systemic skeletal disease characterized by low bone mass and micro architectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. This well-established definition, developed by the international consensus in 1993, captures two important characteristics of the disease: its adverse effects on bone mass and microstructure, and the clinical outcome of fracture.

 

Some of the key facts of the Osteoporosis Market Report: 

  • The Osteoporosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The total diagnosed prevalent population of osteoporosis in the 7MM was 29,700,822 cases in 2021. While, the total diagnosed prevalent population of Osteoporosis in the United States was found to be 6,890,048 cases in 2021, which is expected to increase by 2032
  • As per the National Institute of Health Osteoporosis and Related Bone Diseases National Resource Center, in the United States, more than 53 million people either already have osteoporosis or are at high risk due to low bone mass
  • According to a study conducted by Bolster et al. titled “Osteoporosis” states that about 8 million women and 2 million men in the United States have osteoporosis
  • Key Osteoporosis Companies: Haoma Medica, Jiangsu HengRui Medicine, and others
  • Key Osteoporosis Therapies: NaQuinate, SHR-1222, and others
  • The Osteoporosis epidemiology based on gender analyzed that Osteoporosis is more in females as compared to males

 

Get a Free sample for the Osteoporosis Market Report –

https://www.delveinsight.com/sample-request/osteoporosis-market

 

Key benefits of the Osteoporosis Market report:

  1. Osteoporosis market report covers a descriptive overview and comprehensive insight of the Osteoporosis Epidemiology and Osteoporosis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Osteoporosis market report provides insights on the current and emerging therapies.
  3. Osteoporosis market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Osteoporosis market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Osteoporosis market.

 

Download the report to understand which factors are driving Osteoporosis epidemiology trends @ Osteoporosis Epidemiological Insights 

 

Osteoporosis Market  

The dynamics of the Osteoporosis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“The pipeline of Osteoporosis is not robust consisting of only two products in clinical developmental stages. These include Alendronate/Zoledronic Acid by Amgen and NaQuinate or OsteopurabyHaoma Medica in phase II and phase I stage of clinical development respectively.”

 

Osteoporosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Osteoporosis Epidemiology Segmentation:

The Osteoporosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Osteoporosis
  • Prevalent Cases of Osteoporosis by severity
  • Gender-specific Prevalence of Osteoporosis
  • Diagnosed Cases of Episodic and Chronic Osteoporosis

 

Osteoporosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Osteoporosis market or expected to get launched during the study period. The analysis covers Osteoporosis market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Osteoporosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Osteoporosis market share @ Osteoporosis market forecast 

 

Osteoporosis Therapies and Key Companies

  • NaQuinate: Haoma Medica
  • SHR-1222: Jiangsu HengRui Medicine

 

Osteoporosis Market Drivers

  • Osteoporotic prevention organizations  
  • Risk Factors related to Osteoporosis

 

Scope of the Osteoporosis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Osteoporosis Companies: Haoma Medica, Jiangsu HengRui Medicine, and others
  • Key Osteoporosis Therapies: NaQuinate, SHR-1222, and others
  • Osteoporosis Therapeutic Assessment: Osteoporosis current marketed and Osteoporosis emerging therapies
  • Osteoporosis Market Dynamics: Osteoporosis market drivers and Osteoporosis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Osteoporosis Unmet Needs, KOL’s views, Analyst’s views, Osteoporosis Market Access and Reimbursement 

 

Osteoporosis Market Barriers

  • Adverse Events
  • Under-diagnosis
  • Lack of proactive throughput
  • Generics and Biosimilars

 

Table of Contents 

1. Osteoporosis Market Report Introduction

2. Executive Summary for Osteoporosis

3. SWOT analysis of Osteoporosis

4. Osteoporosis Patient Share (%) Overview at a Glance

5. Osteoporosis Market Overview at a Glance

6. Osteoporosis Disease Background and Overview

7. Osteoporosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Osteoporosis 

9. Osteoporosis Current Treatment and Medical Practices

10. Osteoporosis Unmet Needs

11. Osteoporosis Emerging Therapies

12. Osteoporosis Market Outlook

13. Country-Wise Osteoporosis Market Analysis (2019–2032)

14. Osteoporosis Market Access and Reimbursement of Therapies

15. Osteoporosis Market Drivers

16. Osteoporosis Market Barriers

17.  Osteoporosis Appendix

18. Osteoporosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Osteoporosis treatment, visit @ Osteoporosis Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting

  Categories: